Aptevo Therapeutics (NASDAQ:APVO) Posts Quarterly Earnings Results, Beats Estimates By $126.33 EPS

Aptevo Therapeutics (NASDAQ:APVO) posted its quarterly earnings data on Friday. The biotechnology company reported $118.23 earnings per share for the quarter, topping analysts’ consensus estimates of ($8.10) by $126.33, FiscalAI reports.

Aptevo Therapeutics Stock Down 5.3%

Aptevo Therapeutics stock opened at $4.27 on Friday. Aptevo Therapeutics has a 52-week low of $3.95 and a 52-week high of $1,299.60. The firm has a market cap of $4.27 million, a PE ratio of 0.00 and a beta of 1.44. The company’s 50 day moving average is $6.53 and its two-hundred day moving average is $17.01.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings restated a “sell (e)” rating on shares of Aptevo Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded Aptevo Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by hedge funds and other institutional investors.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.